CoChat
Sign Up
Cited by 71

Arm Selection Preference of MicroRNA-193a Varies in Breast Cancer

Tsai, Kuo-Wang, Leung, Chung-Man, Lo, Yi-Hao, Chen, Ting-Wen, Chan, Wen-Ching, Yu, Shou-Yu, Tu, Ya-Ting, Lam, Hing-Chung +4 more·2016·Scientific Reports
DOI 10.1038/srep28176PMC PMC4910092
Open this paper in CoChat — free account

Abstract

MicroRNAs (miRNAs) are short noncoding RNAs derived from the 3′ and 5′ ends of the same precursor. However, the biological function and mechanism of miRNA arm expression preference remain unclear in breast cancer. We found significant decreases in the expression levels of miR-193a-5p but no significant differences in those of miR-193a-3p in breast cancer. MiR-193a-3p suppressed breast cancer cell growth and migration and invasion abilities, whereas miR-193a-5p suppressed cell growth but did not influence cell motility. Furthermore, NLN and CCND1, PLAU, and SEPN1 were directly targeted by miR-193a-5p and miR-193a-3p, respectively, in breast cancer cells. The endogenous levels of miR-193a-5p and miR-193a-3p were significantly increased by transfecting breast cancer cells with the 3′UTR of their direct targets. Comprehensive analysis of The Cancer Genome Atlas database revealed significant differences in the arm expression preferences of several miRNAs between breast cancer and adjacent normal tissues. Our results collectively indicate that the arm expression preference phenomenon may be attributable to the target gene amount during breast cancer progression. The miRNA arm expression preference may be a means of modulating miRNA function, further complicating the mRNA regulatory network. Our findings provide a new insight into miRNA regulation and an application for breast cancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep28176

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The abundance of miR-193a-5p, but not miR-193-3p, is significantly decreased in breast cancer and is believed to be due to reduced availability of miR-193a-5p targets.

    “The abundance of miR‐193a‐5p, but not miR‐193‐3p is significantly decreased in breast cancer and is believed to be due to reduced availability of miR‐193a‐5p targets (Tsai et al., 2016).”

    From microRNA strand selection: Unwinding the rules (2021) · cites this paper as Tsai et al., 2016

  • The ratio of miR::miR* strands may be influenced by target availability, as the presence of suitable mRNA targets can stabilize cognate miRNAs.

    “It has been suggested that the ratio of miR::miR* strands may be influenced by target availability, as the presence of suitable mRNA targets can stabilize cognate miRNAs (Chatterjee, Fasler, Büssing, & Großhans, 2011; Tsai et al., 2016).”

    From microRNA strand selection: Unwinding the rules (2021) · cites this paper as Tsai et al., 2016

  • The strand bias of miR-193a appears to be altered in breast cancer cell lines, as well as patient tissues.

    “Similarly, the strand bias of miR‐193a appears to be altered in breast cancer cell lines, as well as patient tissues (Tsai et al., 2016).”

    From microRNA strand selection: Unwinding the rules (2021) · cites this paper as Tsai et al., 2016

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. Gravgaard K. H.. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res and Treat 134, 207– 217, doi: 10.1007/s10549-012-1969-9 (2012). 22294488 · DOI
  2. Yekta S., Shih I. H. & Bartel D. P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594– 596 (2004). 15105502
  3. Newman M. A. & Hammond S. M. Emerging paradigms of regulated microRNA processing. Genes Dev 24, 1086– 1092 (2010). 20516194 PMC2878647
  4. Trabucchi M.. How to control miRNA maturation? RNA Biol 6, 536– 540, doi: 10080 (2009). 19875945
  5. Slezak-Prochazka I., Durmus S., Kroesen B. J. & van den Berg A. MicroRNAs, macrocontrol: regulation of miRNA processing. RNA 16, 1087– 1095 (2010). 20423980 PMC2874160
  6. Leung C. M.. Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. Oncol Rep 31, 1067– 1078, doi: 10.3892/or.2014.2988 (2014). 24452514 PMC3926670 · DOI
  7. Cheng W. C.. YM500: a small RNA sequencing (smRNA-seq) database for microRNA research. Nucleic Acids Res 41, D285– 294, doi: 10.1093/nar/gks1238 (2013). 23203880 PMC3531161 · DOI
  8. Li S. C.. miRNA arm selection and isomiR distribution in gastric cancer. BMC genomics 13 Suppl 1, S13 (2012). 22369582 PMC3303722
  9. Chang H. T.. Comprehensive analysis of microRNAs in breast cancer. BMC genomics 13 Suppl 7, S18, doi: 10.1186/1471-2164-13-S7-S18 (2012). 23281739 PMC3521236 · DOI
  10. Li S. C.. Interrogation of rabbit miRNAs and their isomiRs. Genomics 98, 453– 459 (2011). 21930198
  11. Griffiths-Jones S., Hui J. H., Marco A. & Ronshaugen M. MicroRNA evolution by arm switching. EMBO Rep 12, 172– 177, doi: 10.1038/embor.2010.191 (2011). 21212805 PMC3049427 · DOI · Paper page
  12. Marco A., Hui J. H., Ronshaugen M. & Griffiths-Jones S. Functional shifts in insect microRNA evolution. Genome Biol Evol 2, 686– 696, doi: 10.1093/gbe/evq053 (2010). 20817720 PMC2956262 · DOI · Paper page
  13. Li S. C.. MicroRNA 3′ end nucleotide modification patterns and arm selection preference in liver tissues. BMC Syst Biol 6 Suppl 2, S14, doi: 10.1186/1752-0509-6-S2-S14 (2012). PMC3521178 23282006 · DOI
  14. Lv L.. The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death Dis 5, e1402, doi: 10.1038/cddis.2014.367 (2014). 25188512 PMC4540198 · DOI
  15. Wang J.. Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines. Cell Physiol Biochem 32, 1707– 1719, doi: 10.1159/000356605 (2013). 24356455 · DOI
  16. Ma K.. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Bio Chem 287, 5639– 5649, doi: 10.1074/jbc.M111.291229 (2012). 22117060 PMC3285337 · DOI
  17. Heller G.. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 18, 1619– 1629, doi: 10.1158/1078-0432.CCR-11-2450 (2012). 22282464 · DOI
  18. Kozaki K., Imoto I., Mogi S., Omura K. & Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68, 2094– 2105, doi: 10.1158/0008-5472.CAN-07-5194 (2008). 18381414 · DOI
  19. Iliopoulos D., Rotem A. & Struhl K. Inhibition of miR-193a expression by Max and RXRalpha activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res 71, 5144– 5153, doi: 10.1158/0008-5472.CAN-11-0425 (2011). 21670079 PMC3148313 · DOI
  20. Salvi A.. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer 12, 162, doi: 10.1186/1476-4598-12-162 (2013). 24330766 PMC4029516 · DOI
  21. Deng H.. miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer 13, 234, doi: 10.1186/1476-4598-13-234 (2014). 25311867 PMC4200202 · DOI
  22. Deng H.. The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta 1852, 520– 528, doi: 10.1016/j.bbadis.2014.12.014 (2015). 25542424 · DOI
  23. Li Y.. The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget 6, 10195– 10206 (2015). 25991669 PMC4496349
  24. Liang H.. miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4. J Biol Chem 290, 926– 940, doi: 10.1074/jbc.M114.621409 (2015). 25391651 PMC4294520 · DOI
  25. Williams M.. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget 6, 23480– 23495, doi: 10.18632/oncotarget.4346 (2015). 26125439 PMC4695131 · DOI
  26. Yu T.. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene 34, 413– 423, doi: 10.1038/onc.2013.574 (2015). 24469061 · DOI
  27. Lv L.. MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett 357, 105– 113, doi: 10.1016/j.canlet.2014.11.002 (2015). 25444900 · DOI
  28. Yang Y.. A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma. Oncogene 32, 3432– 3442, doi: 10.1038/onc.2012.360 (2013). 22907428 · DOI
  29. Wu H. H., Lin W. C. & Tsai K. W. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med 16, e1, doi: 10.1017/erm.2013.16 (2014). 24456939 PMC3908627 · DOI
  30. Chatterjee S., Fasler M., Bussing I. & Grosshans H. Target-mediated protection of endogenous microRNAs in C. elegans. Dev cell 20, 388– 396, doi: 10.1016/j.devcel.2011.02.008 (2011). 21397849 · DOI · Paper page
  31. Chatterjee S. & Grosshans H. Active turnover modulates mature microRNA activity in Caenorhabditis elegans. Nature 461, 546– 549, doi: 10.1038/nature08349 (2009). 19734881 · DOI
  32. Rand T. A., Petersen S., Du F. & Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123, 621– 629, doi: 10.1016/j.cell.2005.10.020 (2005). 16271385 · DOI
  33. Hu W., Wang T., Yue E., Zheng S. & Xu J. H. Flexible microRNA arm selection in rice. Biochem Biophys Res Commun 447, 526– 530, doi: 10.1016/j.bbrc.2014.04.036 (2014). 24746469 · DOI
  34. Choo K. B., Soon Y. L., Nguyen P. N., Hiew M. S. & Huang C. J. MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J Biomed Sci 21, 95, doi: 10.1186/s12929-014-0095-x (2014). 25287248 PMC4195866 · DOI
  35. Ory B.. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 121, 809– 820, doi: 10.1172/JCI43897 (2011). 21293058 PMC3026726 · DOI
  36. Gao X. N.. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 30, 3416– 3428, doi: 10.1038/onc.2011.62 (2011). 21399664 · DOI
  37. Li Y.. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 121, 499– 509, doi: 10.1182/blood-2012-07-444729 (2013). 23223432 · DOI
  38. Xuan F.. Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1. Neuro Oncol, doi: 10.1093/neuonc/nov281 (2015). PMC4864258 26582930 · DOI
  39. Yang L.. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14, 124, doi: 10.1186/1471-2407-14-124 (2014). 24564888 PMC3936852 · DOI
  40. Renjini A. P.. STAT3 and MCL-1 associate to cause a mesenchymal epithelial transition. J Cell Sci 127, 1738– 1750, doi: 10.1242/jcs.138214 (2014). 24481815 · DOI
  41. Kim D. Y., Ingano L. A., Carey B. W., Pettingell W. H. & Kovacs D. M. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. J Biol Chem 280, 23251– 23261, doi: 10.1074/jbc.M412938200 (2005). 15833746 · DOI
  42. Tsai K. W.. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes, Chromosomes Cancer 51, 394– 401 (2012). 22420029

Cited by

Sorted by citations

Authors
Tsai, K.-W., Leung, C.-M., Lo, Y.-H., Chen, T.-W., Chan, W.-C., Yu, S.-Y., Tu, Y.-T., Lam, H.-C., Li, S.-C., Ger, L.-P., Liu, W.-S., & Chang, H.-T.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2016-06-16
Volume
6
Issue
1
ISSN
2045-2322
DOI
10.1038/srep28176
PMC
PMC4910092
Cited by
71
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review